BitDeer.com Launches Antminer S19 Pro Acceleration Plan

SINGAPORE – (ACN Newswire) – BitDeer.com, the first computing power sharing platform to launch the highly anticipated Antminer S19 Pro mining plans, unveils an innovative acceleration plan for users, which would speed up the process of returns.

BitDeer.com is launching an acceleration plan that allows customers who purchase their S19 Pro mining plans to gain returns at a faster rate. It comes fully loaded with a multitude of variances for the consumer in order to maximize the return catered to their needs. This announcement comes after news that the S19 Pro plans that first debuted on Bitdeer.com were sold out within 2 minutes of its release. For a limited period, purchasers of S19 Pro mining plans are able to enjoy up to 50 free mining days. With low power consumption and the longstanding trust the platform has built and nurtured with suppliers and mining pools, BitDeer.com has provided this unique computer power sharing package to further accommodate their community.

Following the drop of prices, Chief Marketing Officer, Ray Shi, stated that “security is of the utmost concern for users with bearish sentiments”. The classic plans have a higher ROI for long-term customers, while this new plan gives options to its users who are looking for faster returns, giving customers with varying sentiments and preferences towards the market an opportunity to gain during different conditions. The new plan boasts a design in which the purchase cost is relatively low, which would be favourable for users who aim to recover their mining investments faster and allow them to actively respond to changes in market conditions. Under the accelerated plan, the platform has zero initial profits and even subsidies. Every day when the accumulated mining revenue minus the paid electricity fee is less than the computing power cost, users get all the earnings during this period. Meanwhile, if the amount is equal to or greater than the computing power cost, earnings would be calculated on a daily basis and distributed accordingly. If the calculation is negative, there will not be any return distribution.

With their flexibility in offering a wide variety of currencies, varying cycle lengths and more options and opportunities, BitDeer.com differentiates itself from its competitors by being customer-focused. During the recent price dip, a subsidy policy for T15 plans ( https://twitter.com/BitDeerOfficial/status/1238458317485137921 ) which has now ended, allowed users to apply for suspension of electricity delay mining. For more information on BitDeer.com and their initiatives, please visit the official website.

About BitDeer

BitDeer is the world’s leading computing power-sharing platform, enabling global users to mine cryptocurrencies in a transparent, reliable, and convenient way. It saves users from the complicated process of purchasing, installing, and hosting mining machines. Individual miners can enjoy the service with just one click.

For more information, please visit:

Website: https://www.BitDeer.com

Facebook: https://www.facebook.com/BitDeerplatform

Twitter: https://twitter.com/BitDeerOfficial

YouTube: https://www.youtube.com/watch?v=lu95K9N5CM4

VK: https://vk.com/public174640639

Media Contact

MagicFew

Email: hello@magicfew.com

Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress

HONG KONG, Mar 30, 2020 – (ACN Newswire) – Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provides an update on the Company’s operations in light of the recent declaration of the coronavirus outbreak as a pandemic declared by the World Health Organisation on March 11, 2020.

Aptorum Group’s operational plans continue to remain on track, and in particular the recently announced updates on SACT-1 (targeting Neuroblastoma) and ALS-4 (targeting Staphylococcus aureus) remain on track for its pre-IND preparation work and will continue to target for IND submission in the second half of 2020. With the additional capital raised in February 2020, the Company is also on track in expanding strategic initiatives including the discovery and development pipeline such as the recently announced initiative SACT-COV19 (targeting COVID-19 disease) and additional Smart-Act platform projects being SACT-2 and SACT-3, which will be announced in due course. The Company, together with the distributor, is also focused on the distribution of the recently announced non-hormonal based Dioscorea Opposita bioactive nutraceutical supplement targeting woman’s health during menopause or post-menopause cycles. In light of the global coronavirus situation, the Company would like to report that its day to day operations continue to proceed as normal.

The management of the Company will also host its first quarter 2020 investor update conference call to discuss recent developments and plans for the Company on Thursday, April 2, 2020. Aptorum Group will also provide updates during the call on the progress of its existing pipeline, including SACT-1 and ALS-4, and the latest announced project targeting the coronavirus group including COVID-19. A conference call will be held on Thursday, April 2, 2020 at 10:00am Hong Kong time (April 1, 2020 at 10:00pm EST) by the executive management team. If you have any specific question(s) for the Company and its projects, please email your question(s) to investor.relations@aptorumgroup.com on or before 10:00pm EST Tuesday, March 31, 2020.
To participate in the call, please dial +852 3018 8307 (for Hong Kong callers) or 1-844-760 0770 (for US callers) using conference ID number 6995532. The archived webcast will be available on the Investors section of Aptorum Group’s website (http://ir.aptorumgroup.com/) approximately one hour after the call has completed.

About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline include indications in orphan diseases, infectious diseases and metabolic diseases and a number of which are targeted to enter clinical trial phases in 2020. Aptorum Group also operates a woman’s health supplement business whose Dioscorea Opposita Bioactive Nutraceutical Tablets are currently being commercialized.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Contacts
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com

Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com

Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT Platform and Acticule Infectious Disease Platform

HONG KONG – (ACN Newswire) – Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas, today announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and has also entered into agreement with the University of Hong Kong’s Microbiology Department to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies to initiate clinical trials on suitable candidates.

In particular, Aptorum Group will focus on investigation of at least three small molecule drugs (collectively “SACT-COV19”), that have shown potential interference against two enzyme targets, namely, 3CL-Protease and RNA dependent RNA Polymerase (“RDRP”), with both playing pivotal roles in COVID-19’s replication cycle. Specifically, 3CL-Protease is believed to mediate viral replication and transcription functions through extensive proteolytic processing, while RDRP is an enzyme that is believed to catalyze the replication of viral RNA from its RNA template. These selected candidates will undergo further preclinical assessment on efficacy against COVID-19. Aptorum Group has filed patent applications on the above candidates.

For the ongoing investigation and preclinical work, Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and also Aptorum Group has contracted with the University of Hong Kong to conduct this work. Covar Pharmaceutical’s team (comprised of professionals previously from Patheon and Glaxo Wellcome)1 is highly experienced in drug discovery and development supported by its GMP manufacturing facility. The University of Hong Kong’s Microbiology team was instrumental in the discovery of SARS virus during the 2003 epidemic2, as well as currently being actively involved, in their own respective research interests, in developing vaccines for SARS-CoV-2 coronavirus3 and COVID-19 related monitoring physical device with other third parties4.
Aptorum Group will also seek additional collaborators globally for driving its development of SACT-COV19 initiatives forward and welcomes interested parties to contact us to discuss collaboration opportunities.

Aptorum Group, as part of its existing pipeline, is also developing a number of infectious disease indications under its Acticule platform, including, but not limited to, a unique antiviral small molecule candidate (ALS-1) against Influenza virus and also, as its lead program, an anti-virulent, non-bactericidal small molecule candidate (ALS-4) against Staphylococcus aureus infections, amongst other projects, for which Covar Pharmaceuticals is also currently supporting its development in North America.

Mr. Ian Huen, Chief Executive Officer of Aptorum Group said, “COVID-19 disease is highly contagious and has spread across the world causing significant disruptions and casualties in the process. The confirmed cases globally have exceeded 700,000 as of today’s date5 and the World Health Organization has declared COVID-19 as a pandemic. Despite a growing number of both established and early stage pharmaceutical companies rushing to develop vaccine based therapies for COVID-19, we believe there is a need to tackle this disease multi-dimensionally and urgently. In order to accelerate development, our aim is to identify candidates from already approved drugs, that have established safety, toxicity and pharmacokinetic clinical profiles, to be repurposed for treatment of COVID-19. In addition, due to the ongoing mutation and evolution of this coronavirus, we cannot rule out that there may be further strains of this coronavirus emerging in the near future and therefore, the world must be prepared to deal with such challenges swiftly and collectively in order to minimize casualties and economic loss. We believe that Aptorum Group’s Smart-ACT platform in conjunction with our existing Acticule infectious disease development capabilities and as supported by Covar Pharmaceuticals, is well-positioned to develop potential solutions and to deliver our share of contribution to the world on this disease as well as others.”

About Smart-ACT Platform
The Smart-ACT platform is a proprietary systematic process combining both computational approach and wet laboratory validation under which Aptorum Group constantly screens over 2,600 approved small molecule drugs in order to identify candidates that can be repurposed for selected orphan or unmet diseases. The overall strategic aim is to significantly shorten R&D costs and the timeline to effectively deliver patentable repurposed drug candidates into clinical trials and efficiently achieve eventual market commercialization.

About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline include indications in orphan diseases, infectious diseases and metabolic diseases and a number of which are targeted to enter clinical trial phases in 2020. Aptorum Group’s Dioscorea Opposita Bioactive Nutraceutical Tablets, which is a dietary supplement for women’s health during menopause and post-menopause cycles, are currently being commercialized.
For more information about Aptorum Group, please visit http://www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

https://www.covarpharma.com/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747526/
https://fightcovid19.hku.hk/tag/vaccine/
https://www.scmp.com/business/article/3073869/hong-kong-researchers-join-us-tech-start-remotely-monitor-covid-19
https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

Contacts
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com

Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com

GeoMap Clinical Platform Introduces Video Visit Links to Connect Patients with Sites to Boost Recruitment

SAN FRANCISCO, CA, Mar 30, 2020 – (ACN Newswire) – Award-winning global digital patient recruitment Platform GeoMap Clinical said it was making video visits (telemedicine, telehealth), instantly available to patients with services like Zoom, WhatsApp, Google, Skype and Facebook, via SMS messages and email to screened eligible patients.

The GeoMap Platform finds, screens, and then sends patients direct to sites via email and doesn’t keep their information. Recruitment starts in 24 hours and doesn’t require IRB/EC approvals.

The Platform’s new video service allows simple one click connections for sites and patients to engage via video for their first screening “visit” and ongoing communications and check-ins.

In addition, rather than a typical tick box question and answer screener, GeoMap uses an advanced AI conversational speech or typing technology to determine eligibility – making it easy for young and old potential patients.

The GeoMap Platform recruits and screens patients online. Advanced algorithms find the right patients via news websites, social media, health and wellness websites and more, and connects eligible people with sites via encrypted email.

The GeoMap Platform recruits for clinical trials in North America, Latin America, Australia, New Zealand, China, South Korea, Singapore, Thailand, and the EU.

The company said: “Recent recruitment data from the GeoMap Platform showed 48% of people preferred telemedicine and home visits instead of clinic appointments. GeoMap is working closely with biotechs and CROs around the world to keep screening patients and connecting them with study coordinators online to support important ongoing clinical research amid the COVID-19 crisis. GeoMap also offers a pre-recruitment service for studies on temporary hold or those about to start.”

The GeoMap Platform is a 3-step process:
1. Find the right patients online using advanced algorithms across country specific social and news media, as well as video and online search
2. Screen them using the Proprietary AI Patient Screener Funnel of more than 300+ possible questions
3. Connect them to sites via direct secure encrypted email to the study coordinator/s for a phone call.

The Platform is the fastest most accurate targeting tool available that doesn’t require IRB/EC approval and can start recruiting in under 24 hours. The Platform has strict verification and email encryption so PHI is managed in accordance with state and country regulatory guidelines.

For more information and pricing please click here: https://www.geomapclinical.com/start-today/

About GeoMap

The GeoMap Clinical Platform is the world’s most advanced geo-location/targeting and AI platform powered by specialist algorithms that find and screen the right people living or working near sites. The Platform is a sophisticated location and health profile search service that sends only highly eligible people to their nearest site.

GeoMap has been designed to end pain points across the clinical trials sector saving time and money at every stage, while ensuring patient privacy and regulatory compliance. The GeoMap Clinical Platform is not a database builder. Patient ID is redacted instantly and the focus is instead on finding only motivated patients to support enrolment and retention. For a tour of the platform, visit: https://www.trial-wire.com/.

For a briefing please click here: https://www.geomap-clinicaltrialfinder.com/patient-recruitment-covid-19/

Media Contact
Chris Thompson
team@dmgpr.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

EXO’s Suho celebrates his first solo EP “Self-Portrait” with a ‘Live’ #TwitterBlueroom Session

“Fans await with high expectations for the #TwitterBlueroom Live Q&A with Suho”
– Suho of EXO is set to hold a live Q&A session on #TwitterBlueroom to celebrate the release of his first EP, “Self-Portrait”
– Suho will unbox his album for the first time live on #TwitterBlueroom
– Winning submissions from # [*1] (Drawing Contest for the World’s Best Suho) will also be announced and featured

Twitter Korea will host a ‘live’ #TwitterBlueroom Q&A session with Suho, member of the popular Kpop boy band EXO (@weareoneEXO), on March 26th at 6PM KST. A special emoji has been created in line with the theme of his first EP titled “Self-Portrait,” which will appear automatically when fans use the hashtags #SUHO, #Self_Portrait, and #LetsLove from March 26th onwards. Suho’s first solo EP will be officially released on March 30th.

https://twitter.com/weareoneEXO/status/1242420926685138948
Photograph: Suho’s Tweet announcing his live Q&A session on #TwitterBlueroom

In this special Q&A session, Suho will share more about his new album “Self-Portrait,” his plans as a solo artist, and what he has been up to recently. Fans can watch the live #TwitterBlueroom on EXO’s official Twitter account (@weareoneEXO), and interact with him directly using the hashtags #TwitterBlueroom and #SUHO, or within the live chatroom.

Furthermore, Suho will be doing a special unboxing segment during his live #TwitterBlueroom. He will unveil his EP package for the first time, which consists of an album cover, booklet, postcards, as well as regular and special photo cards.

Suho will also feature the winning illustrations from the drawing contest entered using the hashtag # [*1] (Drawing Contest for the World’s Best, SUHO) held on EXO’s official Twitter account (@weareoneEXO) earlier this month. Fans had to post illustrations of SUHO on Twitter with the hashtags, #SUHO, #Self_Portrait, # [*1], and more. The contest received overwhelming submissions from fans all around the world, propelling the hashtag # [*1] to trend as it had more than 100,000 mentions between March 12th to 20th (data as of March 24th).

Meanwhile, after Suho Tweeted a video teasing his EP promotion schedule on March 16; the hashtag # [*2] (Our Jun-myeon), which is Suho’s real name, quickly trended No. 1 on Twitter. The hashtag #AskSUHO also trended No. 1 worldwide on Twitter after he Tweeted about his #TwitterBlueroom on March 24.

Check out the hashtags #SUHO, #Self_Portrait, and #LetsLove; or follow @weareoneEXO to stay updated with Suho’s first EP launch and what’s happening on Twitter!

About Twitter

Twitter, Inc. (NYSE: TWTR) is what’s happening in the world and what people are talking about right now. On Twitter, live comes to life as conversations unfold, showing you all sides of the story. From breaking news and entertainment to sports, politics and everyday interests, when things happen in the world, they happen first on Twitter. Twitter is available in more than 40 languages around the world. The service can be accessed at twitter.com, on a variety of mobile devices and via SMS. For more information, visit about.twitter.com or follow @TwitterKorea. For information on how to download the Twitter and Periscope apps, visit twitter.com/download and periscope.tv.

Media Contact
Heejung Shin
Twitter Korea
Email: Heejungs@twitter.com
Twitter: @xinxi1

Some terms in this release are displayed in Korean as indicated with asterisk. Please refer to the full release at https://www.media-outreach.com/View/31079/

Nissin Foods as the Exclusive Food Partner of SF&OC to support local athletes at Tokyo 2020

Nissin Foods' ambassador "Ching Chai" took a video to cheer up local athletes. Stay tuned!
Nissin Foods’ ambassador “Ching Chai” took a video to cheer up local athletes. Stay tuned!

Cheer for the Hong Kong athletes who are prepping for the Olympic Games at Tokyo! Nissin Foods (Stock code: 1475) announced the company will join the chorus to support these local elite athletes through team-up with the Sports Federation & Olympic Committee of Hong Kong, China (SF&OC) as the “Exclusive Food Partner of Hong Kong, China’s Delegation to the Tokyo 2020 Olympic Games.”

Although the Tokyo Olympics is postponed due to the epidemic, which has greatly affected the training schedule of athletes, by adhering to its corporate slogan of “HUNGRY to WIN”, Nissin Foods has decided to embrace the challenges and stand by with Hong Kong’s elite athletes. Partnering with SF&OC, Nissin Foods also wishes to enhance public awareness and support for the Hong Kong athletes. Local elite athletes have been prepping for the Tokyo Olympics for years, and quite a good number have secured a place.

Mr Kiyotaka Ando, Executive Director, Chairman of the Board and Chief Executive Officer of Nissin Foods, said: “Nissin Foods is pleased to partner with SF&OC and feels excited to extend our support to the Olympic-qualified athletes from Hong Kong. We also wish to see more local athletes securing a ticket for the Tokyo Olympics. No matter when it is going to take place, we look forward to seeing the Hong Kong athletes shine in the international sports arena in the coming Olympic Games in Tokyo.”

He added: “In face of the challenges, Nissin Foods takes it as part of our corporate social responsibility to provide consumers with a stable and reliable supply of quality food. Similarly, when the Olympics community and athletes are facing the impact of the epidemic, it is time for us to unite our forces to support them. While affirming their efforts and achievements, Nissin Foods also appeals to the public to cheer for the Hong Kong teams so that they could strive for good results in the Tokyo Olympics.”

The goal of the Olympic Movement is to contribute to building a peaceful and better world by educating youth through sport practiced without discrimination of any kind, while promoting friendship, solidarity and fair play. This, together with Nissin’s corporate slogan of “HUNGRY to WIN” striving for innovation in the global food industry, Nissin Foods is no stranger to sports development sponsorship in Hong Kong, and in particular, bolstering the Junior Tennis development through partnering with the Hong Kong Tennis Association.

As part of the collaboration with the SF&OC, Nissin Foods will take part in this year’s Festival of Sport and Olympic Day organised by the Federation, in a bid to beef up public excitement and garner public support for local athletes in the lead-in to the Tokyo 2020.

Nissin Foods’ ambassador “Ching Chai” took a video to send cheer to local athletes:
https://youtu.be/pK1veKFBwJw

About Nissin Foods Company Limited
Nissin Foods Company Limited (the “Company”, and together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the PRC with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely “NISSIN” and “DOLL” together with a diversified portfolio of iconic household premium food brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the PRC market, the Group has introduced technology innovation through the “ECO Cup” concept into the market and primarily focuses its sales efforts in first- and second-tier cities located in the eastern and southern parts of the PRC. For more information, please visit www.nissingroup.com.hk.

About Sports Federation & Olympic Committee of Hong Kong, China (SF&OC)
The Amateur Sports Federation & Olympic Committee of Hong Kong was established in 1950. It was formally recognized as a member of the International Olympic Committee (IOC), Olympic Council of Asia (OCA), and East Asian Games Association (EAGA) in 1951, 1952 and 1991 respectively and is responsible for the participation of the Hong Kong Delegation to the Olympic Games, Asian Games and East Asian Games. On 8 March 1999, it was formally renamed Sports Federation & Olympic Committee of Hong Kong, China (SF&OC). At present, there are altogether 79 member associations, i.e. National Sports Association (NSA) under SF&OC, who serves as the spokesman of the sports industry in Hong Kong. For more information, please visit: http://www.hkolympic.org.

For media enquiries:
Nissin Foods Company Limited
Public Relations Department
Blanche Wong / Ceci Leung
Email: pr@nissinfoods.com.hk

For investor enquiries:
Nissin Foods Company Limited
Investor Relations Department
Shingo Yamazaki / Peter Kwok
Email: ir@nissinfoods.com.hk

Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hk
Carven Tsui Tel: (852) 2864 4859 Email: carvensm.tsui@sprg.com.hk
Cara Lau Tel: (852) 2864 4890 Email: cara.lau@sprg.com.hk

EuroEyes’s Revenue in 2019 Rose by 14%, Launch New Clinics and Services in 2020 to Boost Future Growth

EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, stock code: 1846), is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and 25 years of experience with individualised customer-care and principally engaged in the provision of vision correction services in Germany, Denmark and the People’s Republic of China (“the PRC”).

2019 Annual Results Highlights
– Total Revenue for the year 2019 reached approximately EUR49 million, up approximately 14% YoY
– Gross Profit for the year 2019 reached approximately EUR20.3 million, up approximately 16.3% YoY
– Adjusted Gross Profit1 for the year 2019 was approximately EUR20.6 million, up approximately 18.4% YoY
– Adjusted Gross Profit Margin for the year 2019 was 42.1%, increased 1.6 percentage points YoY
– Adjusted Net Profit after tax2 for the year 2019 reached EUR5.7 million, up approximately 4.2% YoY

The Revenue by Geographical Regions
– Total revenue in Germany increased by 12.5% YoY
– Total revenue in the PRC increased by 6.8% YoY
– Total revenue in Denmark increased by 45.7% YoY

EuroEyes is pleased to announce its annual results for the year ended 31 December 2019 (the “Year 2019”).

For the Year 2019, the Group’s revenue increased by approximately 14.0% on a year-on-year (“YoY”) basis to approximately EUR49.0 million, adjusted gross profit increased by 18.4% YoY to approximately EUR20.6 million, and the adjusted gross profit margin was 42.1%, representing a YoY increase of 1.6 percentage points.

In respect of geographical regions, the operating revenue from Germany, the PRC and Denmark was EUR30.2 million, EUR12.9 million and EUR5.8 million accounting for 61.7%, 26.4% and 11.9% of total revenue, respectively. .

In respect of the types of surgery, the total revenue for the Year 2019 generated from lens exchange surgery was EUR22.9 million, accounting for 46.8% of total revenue. Lens exchange surgery consists of monofocal and trifocal lens exchange surgery. The total revenue generated from phakic lens (ICL) surgery was EUR6.7 million, accounting for 13.7% of the total revenue.

During the Year 2019, the Group’s total revenue in Germany increased by 12.5% YoY, of which EUR13.4 million was from lens exchange surgery, representing an increase of 23.8% YoY. The Group’s revenue in Germany has grown each year since 2016 as the Group established its position as the market leader in Germany. In Denmark market, the Group’s revenue for the Year 2019 increased by 45.7% YoY. The Group achieved strong revenue growth in Denmark, mainly as a result of the Company’s effective marketing strategy. In addition, the revenue of lens exchange surgery recorded EUR4.9 million, representing a YoY increase of 39.8%.

During the Year 2019, the Group’s revenue in the PRC increased by 6.8% YoY. The growth rate of the Company’s business in the PRC market is expected to increase as the Group expands operations and executes new marketing strategies throughout the PRC. Revenue generated from lens exchange surgery was EUR4.6 million, representing a YoY increase of 27.8%

Strategic Steps Taken
As a leading vision correction company in the world, EuroEyes is committed to be the go-to eye clinic group in Europe and the PRC as it provides patients with the best service combined with state-of-the art German technology and expertise. The Group is actively expanding its business into the PRC while maintaining top quality of the services in Germany, Denmark, and the PRC.

The Group opened two new clinics in the PRC in 2019. The Hangzhou Clinic commenced its operation in June 2019 while the Beijing (East) Clinic opened in September 2019. Further, the Company began construction of the Chongqing Clinic in December 2019, which is expected to commence its operation along with the new Fuzhou Clinic in 2020. In addition, the Company plans to open two new clinics in Chengdu and Qingdao.

As Chinese households become wealthier, they have a greater disposable income to afford high quality eye treatments. This increase in the middle-class is propelling the growth of the ophthalmic market in the PRC. Since entering the PRC in 2013, EuroEyes has provided advanced German technology and 100% German services to patients with myopia, hyperopia, presbyopia and cataracts, enabling them to have clear vision without glasses. Dr.Jorn Slot Jorgensen, founder and the chairman of EuroEyes has successfully completed over 100,000 ophthalmological surgeries and helped patients in Europe and the PRC to have clear vision without glasses.

New Services Was Launched in EuroEyes Clinics
Around 30 years ago, less than 1 % of the Chinese adult population had diabetes. These levels today, however, have increased to around 12 %. This is approximately 114 million diabetic patients in China. The longer a patient has diabetes, the higher his or her chances of developing diabetic retinopathy. Up to 80% of those who have had diabetes for 20 years or more develop diabetic retinopathy. The Chinese government is paying greater attention to prevent diabetic retinopathy as it is the leading cause of new cases of blindness in adults in China. In recent years, Chinese government initiated the “Chinese type II diabetes prevention and treatment guideline (2017)”, stating that diabetic patients need to have their eye screened once every one to two years (or more frequently depending on his or hers condition). It is estimated that at least 90% of new cases could be reduced with proper treatment and monitoring of the eyes by detecting the disease at its early stage.

Against this backdrop, EuroEyes will launch its new service for eye screening in the PRC in April 2020 subsequent to its successful commence of the same service in Germany and Denmark.

EuroEyes will also launch its new service of EDOF treatment in Germany in the second half of 2020 for the people of age 45-55. Given the ICL treatment has been well received in the market for the people of age over 55, the Company believes the new service will become a new revenue growth driver for the Group as it is expected 75%-80% of the people of age 45-54 would accept vision correction surgery for presbyopia.

Recent Development

As at 18 March 2020, EuroEyes’s clinics in Germany and Denmark saw a steady business growth during the majority time Q1 2020. Adjusted Gross Profit Margin for the year 2019 was 42.1%, increased 1.6 percentage points YoY. Meanwhile, the clinics in the PRC resumed their operation in mid-February and received a strong demand for surgery booking via its online platforms.

The Company has incorporated various measures to minimize the impact from Covid-19, such as opening online consultations and online info lectures, maintaining close connection with patients, operating on a reservation-only basis, taking strict measures on disinfection and cleaning of the clinics and consultation centers etc.

The Company believes the volume of surgery will grow steadily in Germany, Denmark and the PRC market after the end of Convid-19 outbreak based on the indicated interest and recorded bookings.

Dr.Jorn Slot Jorgensen, the Founder, Chairman and CEO of EuroEyes commented, “Thanks to all our supporting parties and diligent staff of the Group, EuroEyes has seen a substantial return as it has experienced outstanding business development in the Year 2019. With the strategy of expansion and strong marketing efforts by the Company, we have seen an aggressive surge in the company’s overall revenue and the growth rate of lens exchange surgery in all three countries where EuroEyes is located. We are extremely pleased with the pace of opening our new clinics and plan to continue opening two to three new clinics each year in the PRC. During the Year 2019, the Group continued to fulfil the huge market demand for vision correction using our in-depth experience and technology. In the coming years, the Company will continue to deploy its strategies and resources with a combination of prudent and proactive approaches with an aim to realise our goal of “Nie wieder Brille!” (No More Glasses).”

About EuroEyes International Eye Clinic Limited
EuroEyes was established in 1993 and is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 25 years of experience with individualized customer care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Denmark and the PRC. The Group’s vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation).

(1) Adjusted gross profit is derived from adding pre-operating expenses for two clinics in the People’s Republic of China (the “PRC”) in 2019 to the gross profit.
(2) Adjusted net profit is derived from adding pre-operating expenses for two clinics in the PRC, listing expenses and foreign exchange loss to the net profit for the year.

Leyou Technologies Announces 2019 Annual Results

Registered Users of Flagship Product Warframe Maintains Growth Momentum;
Total Revenue Reached US$214.2 million

The global market leader in free-to-play multiplayer online games, Leyou Technologies Holdings Limited (“Leyou Technologies”, and its subsidiaries collectively “the Group”; stock code: 1089) is pleased to announce its annual results for the year ended 31 December 2019 ( the “reporting period”).

During the reporting period, total revenue of the Group slightly decreased by 5.9% to US$214.2 million. Gross profit amounted to US$121.8 million (2018: US$141.5 million). The Group’s EBITDA was US$49.6 million (2018: US$67.0 million). Nevertheless, excluding non-recurring items of impairment losses and equity-settled shared-based payment expenses, adjusted EBITDA only reduced slightly by 2.4% to US$83.2 million.

Mr. Xu Yiran, Chairman and Chief Executive Officer of Leyou Technologies said, “2019 was a challenging and inheriting year. Despite a declining trend in the sales of current-generation consoles, the total number of registered users of our flagship product Warframe recorded impressive growth of 19.5% to 57.5 million, affirming the Group’s strong online game development and publishing capabilities. In addition, the co-development agreement between the Group and Amazon Game Studios to co-develop and co-publish a game based on The Lord of the Rings will enable the Group to develop the game on a larger scale with greater complexity of characters and richness in contents and for more platforms. Looking forward, the Group will continue the content updates for Warframe, and proactively expand Warframe to more platforms such as the next-generation consoles and other devices, to maximise returns to all shareholders.”

Business Overview
Game Development and Publishing Business
Game development and publishing business is currently the Group’s main source of revenue. This segment covered several free-to-play (“F2P”) online games distributed globally, as well as a series of new products in development. In terms of financial results, the revenue and profit of this segment were mainly contributed by Warframe, a flagship product of the Group. During the reporting period, large-scale AAA games with themes and gameplay similar to Warframe were launched. The strong market promotion of these highly competitive new products inevitably diverted market attention from Warframe to a certain extent. With the next-generation consoles to be released by the end of 2020, the number of new console players reduced accordingly. Also, due to the size and scale of the development work related to Empyrean, a milestone content update for Warframe, the update cadence was temporarily affected and less new game content was released during the reporting period. The three aforementioned factors impacted the performance of Warframe; revenue of the game consequently reduced by 12.2% year-on-year.

During the reporting period, Warframe remained its position as one of the most popular F2P properties worldwide. Warframe adhered to its strategy in content updates. Subsequent to the successful release of Plains of Eidolon in 2017 and Fortuna in 2018, the Group launched Empyrean, another milestone content update for Warframe. Similar to the addition of open world environments, Empyrean will become another pillar of the Warframe experience which further expands the possibilities for players and future development. Warframe steadily sits amongst the top 10 of all game genres in terms of the number of players and playtime on Stream, and has a 92% positive review score from players. Warframe is one of the top F2P games on PlayStation 4 and Xbox One in terms of revenue, and the game also won the Steam Platinum Best-selling Game (12 games with the highest annual total revenues) and the Games with Highest Simultaneous Online Users (6 games with the highest numbers of simultaneous online users) in 2017, 2018 and 2019 successively, the only non-Valve (Steam’s developer) F2P online game with such accolades on Steam.

The Group actively expanded Warframe to more platforms. Subsequent to the launch on Nintendo Switch in November 2018, Warframe has been officially available on Tencent Wegame since March 2019.

Work-for-hire and Other Businesses
During the reporting period, the Group’s work-for-hire business recorded a total revenue of US$31.2 million, an increase of 22.3% compared to 2018. The increase was mainly contributed by Splash Damage Limited, the Group’s AAA studio located in the UK. After the changes in the senior management team at the end of 2018 and early 2019, the studio adopted a more pragmatic management style with a greater focus on exceptional production quality. It successfully won multiple new deals, achieving steady revenue growth for the business. The Group had a number of new business deals on hand, which will bring stable cash income to the Group.

Other businesses mainly include the sale of merchandise goods, which generated revenue of US$0.9 million during the reporting period (2018: US$0.3 million).

New Products in the Pipeline
The Group continued to create original IPs or work with globally renowned IPs to develop new products. The Group currently has multiple projects under development, including Transformers, Civilization Online and other unannounced projects. Some of these products have entered the final stage of development and are expected to be launched in 2020. During the reporting period, the Group successfully acquired the IP authorisation of The Lord of the Rings, and will develop a F2P massively multiplayer online game based on its grand worldview. Combining the huge organic traffic of popular IP, with the Group’s leading game development and publishing capabilities, the Group is capable to maximise the success rate of turning the new product into a blockbuster.

During the reporting period, the Group developed and published a casual F2P idle role-playing game Endless World. First under online testing in August 2019 on Steam, Endless World has been elected 2019 Game of the Year Award (New Release) on Steam in the same year. The Group continously devoted time and resources in new product lines in hopes of turning them into the Group’s future competitive advantages.

Outlook
As a game changer in the global video game market, the Group is committed to providing more compelling games to a diverse user base while at the same time increasing the revenue growth momentum of the games. The Group will strive to increase the players’ engagement and loyalty of existing major games and release more game contents with higher average revenue per user. The comprehensive product line will lay a solid foundation for the Group’s profit growth in the next few years and bring better returns to its shareholders.

Mr. Xu concluded, “Despite the fluctuation in our financial performance to a certain extent during the reporting period, the management is confident in the Group’s mid to long-term results. In the next few years, the Group will launch more flagship products in the market and bring more joy and pleasure to players. In the meantime, the Group understands that it is an arduous journey to grow a game development business, we will continue to be pragmatic and persistent so as to bring us further. The Group will continue to leverage its proven strategy, excellent products and reliable team, to maximise returns to all shareholders.”

About Leyou Technologies Holdings Limited
Leyou Technologies Holdings Limited (1089.HK) is principally engaged in the development and publishing of online multiplayer PC and console video games. It is a global market leader in the market of free-to-play multiplayer online games. Leyou Technologies owns and invests in multiple world renowned AAA game development studios across the globe, including Digital Extremes and Splash Damage, and publishes several of the most successful free-to-play online multiplayer games worldwide. Seven years since the flagship product Warframe has got online, it maintains a top 10 ranking in all genres in terms of number of players and playtime on Steam, and has a positive review score of approximately 92% from players. In addition to the continual premium updates and improvements to its live games, Leyou Technologies also keeps on investing in the development of new products, such as Civilization Online, Transformers Online and The Lord of the Rings.

Azabu Insights: Update on Temperature’s Impact on the Coronavirus

TOKYO – (ACN Newswire) – On March 6th Azabu Insights proposed a theory that coronavirus seemed to be spreading faster in cold countries than in warm countries. We followed this up with an update on March 11th showing that at that time the data was showing ninety-eight percent of the cases were all in cold countries.

Since then we have had many comments from different people. One very respected business person who works in life sciences, told us he thought it was a, “multivariate problem,” and suggested that, “It’s possible, for example, that infection rate would be strongly correlated with people meeting in enclosed areas will less have outside air circulation.” He was saying that our analysis might be true but it might not be, “because of the temperature,” but because of something that “relates to temperature.”

Another doctor said he thought it was because in spring people go outside more and they are less impacted by the dry air of air conditioning systems.

One hospital vice president, whom we highly respect, responded politely, “I do not think that COVID-19 relates to temperature.”

Our conclusion on March 11th was: “As previously, we conclude that COVID-19 can spread in warm regions but seems to spread much more quickly in colder regions. We hope that countries and regions around the world will aggressively work to keep the virus at bay until the summer months and hope that the warm temperatures will support further containment.”

You can see, then as now, we were certainly not 100% convinced that temperature was the driver or that temperature would save the day. But we do remain optimistic.

As recently as March 21, a virologist, Christian Drosten, who advises the German government in their so-far successful tackling of the coronavirus crisis, expressed some optimism that in the coming months we may have some success beating the virus. When asked about the effect of temperature, he responded: “This effect isn’t likely to be particularly pronounced. It won’t be able to stop the outbreak, but it may help a bit. And combined with the isolation measures, I strongly expect that we will see an impact in a month.” It seems he also was not 100% convinced that higher temperature in summer months would solve things, but he thought it could help and envisioned more success at beating the virus spread in weeks ahead.

Updating Data on Temperature vs. Case Statistics – The Situation Now (March 23rd)

On the other hand, we have had people recently coming to us and saying that they’ve heard that there are more outbreaks in warm countries, like Malaysia and Brazil recently. They ask, “doesn’t this prove the theory wrong?” So, we wanted to take a third look at the data and see what it says now and try to figure out what it means. Here are the results.

First off, the cold countries have moved more to the top of the cases list. The top fifteen countries are now all cold countries, as are twenty-two of the top twenty-five countries by case count.

On a percentage basis, today still ninety-six percent of cases have been in cold countries with only four percent in warm countries.

Our definition of cold countries remains unchanged, with a February temperature below fifteen degrees Celsius defining a cold country and above fifteen degrees delineating a warm country. This is because we found the average temperature in Okinawa in February was sixteen degrees Celsius. At this temperature you can go out wearing shorts during the days but need a light jacket or sweatshirt in the evening.

On the other hand, what the people have said to us is certainly true. Some warm countries have seen outbreaks that are hard to ignore. Brazil (1,546 cases), Australia (1,353 cases), Malaysia (1,306 cases) are the leaders in the warm countries right now. Still this is much lower than the leaders in cold countries, China (81,054 cases), Italy (59,138 cases), and USA (32,783 cases).

Countries and Regions That Have Beaten The Virus

The warm countries of Singapore and Hong Kong, had initially had high case counts, ranking number 17 and 18 for most cases as of March 8th. Countries like these have shown that the virus can essentially be stopped. Singapore now has the 40th most cases and Hong Kong has the 50th most cases. But we feel that they probably beat the virus as much because they dealt very aggressively with it as because of the warm weather there.

After all, China and Korea are cold countries and they’ve shown that by dealing aggressively with COVID-19, they could slow or stop the virus too. China has shown very few cases recently despite it seeming out of control at one point. Korea, which does have a high case count, (probably influenced by aggressive testing), has shown a very low death rate.

The Effect of Testing

What about the effect of testing? There is some thinking that the second order things we?ve talked about are also important. For instance, it might be possible that there is more testing in cold countries than warm countries. We haven’t found reliable data on this for all countries, which would be required, but it is a reasonable thing to consider. Note that we did show a consideration for this by doing a per capita GDP analysis, below.

Cold vs. Warm Country Populations

One reader told us they thought there might be more cold countries in the world or more people living in cold countries. We looked at that but concluded that there are only forty-seven percent of the people living in cold countries, whereas fifty-three percent of the people live in warm countries. So, if anything, this should have counteracted the high percentage of cases in cold countries.

Northern Hemisphere vs. Southern Hemisphere Populations

Another reader asked us about what will happen to the Southern hemisphere in July and August. So, we decided to do that analysis as well. Australia concerns us a lot because it has 1,353 cases and will be heading into winter shortly. In Australia most of the population lives in areas where the temperature will be below our fifteen-degree threshold in its coldest month of July.

However, on a further analysis we found that much of the rest of the southern hemisphere population will actually be defined as warm even in the months of July and August. To wit, only nine southern hemisphere countries, representing 2.7% of the world’s population will be colder than fifteen degrees, and classified as a cold country in the month of July. July is typically the coldest month of the year in the Southern Hemisphere. If we were to include northern hemisphere countries that will still be below fifteen degrees in July, such as Russia and Iceland, then we can see that 6.9 percent of the world’s population will be cold in July.

The Effect of Per Capita GDP on Case Counts

Further thinking about “second order considerations” we wanted to look at GDP to see if maybe the colder countries had higher per capita GDP and this was leading to higher COVID-19 case counts. One might argue that this would have led to more travelers to the cold countries, a situation where better healthcare exists, and a situation where more tests have been conducted.

All of these are certainly possible and would push against the idea that temperature itself, or some corollary of temperature is supporting the lower case counts in warm countries.

We looked at GDP in cold and warm countries and found that cold countries have a higher average per capita GDP. In fact, sixty-seven percent of the world’s per capita GDP is in cold countries and thirty-three percent is in warm countries. So, this GDP factor is certainly one that cannot be completely ignored.

It is indeed a possibility that the virus simply spread “first” in cold countries and it will spread in warm countries next.

Still, we feel that 96.0% of all cases being in cold countries can’t be seen as insignificant at this point.

Conclusions

So, what does all of this mean? Does it show that the virus only spreads in cold countries? Does it show that the summer will stop the spread in Europe and North America? Is anything conclusive?

We think that the numbers are telling us four things

A. The spread seems to be faster in colder weather (for whatever reason),

B. The virus can spread in warm countries but seems to spread slower (for whatever reason),

C. The virus can be “beaten” in both warm and cold countries with the right intervention,

D. The summer months are likely to “help” the slow of the spread at least for a few months in Europe and North America, but it will certainly help if Europe and North America continue to take aggressive containment measures.

Separately we think that data is showing that countries that test and treat coronavirus patients in separate “coronavirus only” facilities do much better at containment. Protecting elderly in hospitals and in retirement homes is vitally important to success. This is a topic for another article.

Comments about our analysis are welcome at the email below.

About Azabu Insights

Azabu Insights is a boutique strategic consulting company based in Azabu Juban, Tokyo, Japan. Our teams work collaboratively with clients to build strategies that lead to positive change. Our multilingual team members have top tier academic backgrounds and deep industry experience that we leverage to provide first class, fully engaged, strategic consulting. Core specializations include life sciences, finance, electronics, automotive, aerospace and other industries. For more information contact: info@azabuinsights.com.

Universal Medical Announced its 2019 Annual Results

Revenue Achieved Surge by 58.6%, Proceed with Hospital Group Business

The board (the “Board”) of directors (the “Directors”) of Genertec Universal Medical Group Company Limited (the “Company” or “Universal Medical”) is pleased to announce the annual results of the Company and its subsidiaries (together, the “Group”) for the year ended 31 December 2019.

2019 ANNUAL RESULTS HIGHLIGHTS
– The revenue amounted to approximately RMB6,815.6 million, representing an increase of 58.6% as compared with that of approximately RMB4,296.9 million for 2018.
– The profit before tax amounted to approximately RMB2,211.9 million, representing an increase of 19.0% as compared with that of approximately RMB1,859.0 million for 2018.
– The profit for the year attributable to ordinary shareholders of the parent amounted to approximately RMB1,488.7 million, representing an increase of 10.1% as compared with that of approximately RMB1,352.2 million for 2018.
– The total assets amounted to approximately RMB57,852.5 million, representing an increase of 22.4% as compared with that of approximately RMB47,256.9 million as at 31 December 2018.
– The equity attributable to ordinary shareholders of the parent amounted to approximately RMB9,489.3 million, representing an increase of 13.0% as compared with that of approximately RMB8,395.6 million as at 31 December 2018.
– The return on equity was 16.65% and the return on total assets was 3.11%.

The year of 2019 was a crucial year for Universal Medical to construct a medical and health conglomerate, and push forward the implementation of strategic upgrading. Hospital group continued to expand and their medical finance business steadily developed, the foundation for building an advanced medical and health conglomerate is coming into form. In 2019, the Company revenue increased to RMB6,815.6 million, representing a year-on-year increase of 58.6%. Profit for the year increased to RMB1,634.4 million, representing a year-on-year increase of 21.0%. Profit for the year attributable to ordinary shareholders of the Company increased to RMB1,488.7 million, representing a year-on-year increase of 10.1%.

Further expand hospital group business

Hospital group is the most essential part of building a medical and health conglomerate. In 2019, the Company successively entered into project cooperation contracts with Ansteel Group, Pangang Group, CEC, CR State Asset and Yang Quan Coal Industry through formation of joint ventures or open market bidding, and continued to actively participate in the integration and takeover of medical institutions of SOEs. And the Company has comprehensively improved the medical technology, management efficiency and service capabilities of their hospitals by focusing on discipline construction, operation management, digitalization upgrading, supply chain management, hospital renovation and expansion, and the like.

As at 31 December 2019, the Company had signed contracts in relation to takeover of over 40 medical institutions (including 5 Grade III Class A hospitals and over 20 Grade II hospitals), with an actual capacity of over 15,000 beds. The Company had consolidated the accounts of 24 medical institutions (including 3 Grade III Class A hospitals and 12 Grade II hospitals). The hospital group business performance achieves breakthrough expansion, recorded income of RMB2,046.9 million, representing an increase of RMB1,915.2 million as compared to the previous year, and recorded profit for the year of RMB107.5 million, representing an increase of RMB115.3 million as compared to the previous year.

The Company actively extended its health industry chain around its hospital group. With respect to medical technology, the Company introduced the world’s leading medical device products, and effectively improved the medical technology of hospital customers. As to their medical digitalization business, based on their member hospitals, the Company focused on three key aspects, namely Internet-based healthcare services, smart hospital solutions, and medical big data and artificial intelligence services. By so doing, the Company continuously improved its Internet-based health platform and made great efforts to build an “online+offline” service model. Regarding supply chain management, focusing on the hospital business, the Company carried out construction and deployment of a medicine supply chain system and a management platform of transparent procurement of medical supplies; it also reviewed the use of drugs and medical consumables in each hospital, continuously improved business process and standardized the centralized procurement of regional pharmaceutical supply chains.

Steady development of finance and advisory business

The Company’s medical finance business mainly provides finance lease services for county-level public hospitals. In the past year, on the one hand, the Company continued to expand market development both in depth and width and continuously fortified its business foundation in the face of complicated and changing domestic and foreign financial environment and fierce market competition. On the other hand, the Company continued to strengthen risk control and actively adjusted its financing strategy, and achieved steady development of medical finance business. The Company’s advisory business includes industry, equipment and financing advisory services, and clinical department upgrade services for the prevention, treatment and rehabilitation of CVA and other major diseases with high prevalence. The Company relied on its expanding medical resource platform to improve partner hospitals’ medical technology service capabilities and management efficiency in accordance with specific stages of hospital operation and clinical department development’s characteristics.

In 2019, the finance and advisory business recorded revenue of RMB4,768.6 million, increased by 14.5% as compared to the previous year; recorded gross profit of RMB2,842.2 million, increased by 10.5% as compared to the previous year. Finance lease business recorded revenue of RMB3,807.2 million, increased by 18.4% as compared to the previous year; recorded gross profit of RMB1,890.0 million, increased by 14.6% as compared to the previous year; the net interest spread was 3.24% and the net interest margin was 3.74%, a high ranking among domestic competitors. As at 31 December 2019, the Company’s leased asset reached RMB49,785.6 million, representing an increase of 12.5% as compared with the beginning of the year; non-performing assets ratio was 0.90%, maintaining its leading position of asset quality in the industry.

In the future, Universal Medical will continue to focus on its strategic development direction in medical and healthcare sector and seize policy and market opportunities. Based on the concept of whole life cycle, the Company will strive to build a health industry closed loop centered on medical services and comprising medical finance, medical technology services, medical digitalization and industry chain extension businesses. The Company will actively explore medical and elderly care business, medical health insurance, medical engineering cooperation, regional inspection centers, logistics management and other sectors, and will continue to pool high-quality resources in the industry, improve the layout of the industry, strive to build a trustworthy medical and health conglomerate, and contribute to the construction of “Healthy China”.

About Genertec Universal Medical Group Company Limited
Genertec Universal Medical Group Company Limited (“Universal Medical”) is a diversified medical and health conglomerate focusing on China’s fast developing healthcare service sector, which was listed in Hong Kong in July 2015 (Stock code: 2666). With reliance on modern management concepts, professional teams, high-quality medical resources, solid financial strength and inclusive corporate culture, the Company strives to build up a medical and health conglomerate centered on medical services and engaged in medical finance, medical technology, hospital digitalization and industry chain extension businesses. The controlling shareholder of Universal Medical is China General Technology (Group) Holding Co., Ltd (“Genertec”). Genertec is one of the three central state-owned enterprises focusing on medical industry.

This press release is issued by Genertec Universal Medical Group Company Limited.